January 2008 Vol 7 No 1

Neurophysiological biomarkers for drug development in schizophrenia

Daniel C. Javitt, Kevin M. Spencer, Gunvant K. Thaker, Georg Winterer & Mihály Hajós

doi:10.1038/nrd2463

• Abstract
• Full text
• PDF (1,172KB)

April 2007 Vol 6 No 4

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers

Mark R. Trusheim, Ernst R. Berndt and Frank L. Douglas

p287 | doi:10.1038/nrd2251

• Abstract
• Full text
• PDF (307KB)

April 2007 Vol 6 No 4

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Leslie M. Shaw, Magdalena Korecka, Christopher M. Clark, Virginia M.–Y. Lee and John Q. Trojanowski

p295 | doi:10.1038/nrd2176

• Abstract
• Full Text
• PDF (915 KB)

June 2006 Vol 5 No 6

Diagnostics and biomarker development: priming the pipeline

Kathryn A. Phillips, Stephanie Van Bebber and Amalia M. Issa

p463 | doi:10.1038/nrd2033

• Abstract
• Full text
• PDF (233KB)

Application of intravascular ultrasound in anti-atherosclerotic drug development

Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu and Steven E. Nissen

p485 | doi:10.1038/nrd2040

• Abstract
• Full text
• PDF (598KB)

May 2006 Vol 5 No 5

A role for fMRI in optimizing CNS drug development

David Borsook, Lino Becerra and Richard Hargreaves

p411 | doi:10.1038/nrd2027

• Abstract
• Full text
• PDF (1121KB)

April 2006 Vol 5 No 4

Multiplexed protein measurement: technologies and applications of protein and antibody arrays

Stephen F. Kingsmore

p310 | doi:10.1038/nrd2006

• Abstract
• Full text
• PDF (376KB)